Symbols

TOVX

Theriva Biologics·AMEX

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

Consensus Rating "Strong Buy"

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TOVX

Theriva Biologics, Inc.

A diversified clinical-stage company that developing therapeutics for cancer

Industry

Pharmaceutical

Established Date

Listing Date

06/26/2007

Exchange

American Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.therivabio.com

Security Type

Common stock

Office address

9605 Medical Center Drive, Ste. 270, Rockville, MD 20850

Business

Introduction

Theriva Biologics, Inc. was originally established in 1986. It is a diversified clinical-stage company incorporated in Nevada in 2009 after a series of mergers and name changes. The company focuses on the development of therapies for the treatment of cancer and related diseases, and its lead tumor candidate, VCN-01, is a clinical-stage oncolytic adenovirus designed for intravenous and intravitreal delivery. It also owns other gastroenterology treatment assets.

Company Financials

EPS

TOVX has released its 2025 Q3 earnings. EPS was reported at -0.45, versus the expected -1.13, beating expectations. The chart below visualizes how TOVX has performed over recent quarters, highlighting trends in earnings surprises.